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1106-185 Growth Hormone–Releasing Peptide Can Suppress 
Myocardial Oxidative Stress and Ameliorate 
Progressive Left Ventricular Remodeling in 
Cardiomyopathic Hamsters
Mitsunori Iwase, Sahoko Ichihara, Yosuke Kato, Aya Matsushita, Hiroaki Kanazawa, 
Katsunori Hashimoto, Koji Obata, Kohzo Nagata, Toyoaki Murohara, Mitsuhiro Yokota, 
Takasi Tsunematsu, Yoshihiro Ishikawa, Nagoya University Graduate School of Medicine, 
Nagoya, Aichi, Japan, Yokohama City University, Yokohama, Kanagawa, Japan
Background: Growth hormone-releasing peptide (GHRP) may act directly on the myo-
cardium and improve left ventricular (LV) function, implicating a potential new approach
to the treatment of cardiomyopathic hearts. We hypothesized that cardiac favorable
effects of GHRPs might include the attenuation of myocardial oxidative stress.
Methods and Results: Dilated cardiomyopathic TO-2 hamsters (6 weeks old) were
injected with GHRP-2 (1mg/kg per day, n=8), or saline (n=8) for 6 weeks. F1B hamsters
served as controls (n=8). LV functional and structural changes were evaluated by
echocardiogram and the extents of myocardial oxidative stress were determined by myo-
cardial 4-hydroxy-2-noneal (HNE) concentration as well as the tissue-reduced glutathion,
oxidized glutathione, and the redox ratio (GSH/GSSG). LV fractional shortening (LVFS)
decreased from 53.0 ± 1.4 to 25.1 ± 1.0 % and the LV end-diastolic dimension increased
from 3.7 ± 0.1 to 5.0 ± 0.1 mm in untreated TO-2 hamsters between 6 and 12 weeks.
Both LVFS and LV dimension were substantially improved by treatment with GHRP-2
(41.5 ± 1.5 %, 4.6 ± 0.1 mm, respectively). The ratio of LV dimension / LV wall thickness
in untreated TO-2 hamsters was significantly greater than that in controls (6.42 ± 0.23
Versus 3.73 ± 0.13, p<0.001), and was substantially normalized by the treatment with
GHRP-2 (4.78 ± 0.23). The extent of cardiac fibrosis in TO-2 hamsters with GHRP was
significantly less than that in untreated TO-2 hamsters. The level of HNE in hearts of TO-
2 hamsters was greater than that in controls (1.63 ± 0.14 Versus 0.85 ± 0.08 pmol/mg
protein ), and was normalized by the treatment of GHRP-2 (0.71 ± 0.07 pmol/mg protein).
The redox ratio in hearts of untreated TO-2 hamsters was greater than that in controls
(2.98 ± 0.08 Versus 1.95 ± 0.04, p<0.005) and it was improved by the treatment of
GHRP-2 (2.36 ± 0.08). Myocardial glutathione peroxidase activity in untreated TO-2 ham-
sters was similar to that in F1B hamsters. Conclusion: GHRP can reduce myocardial
oxidative stress during the initial development of LV dysfunction, leading to a favorable
modification of progressive LV remodeling process in dilated cardiomyopathic hamsters.
1106-186 Testosterone Inhibits the α1C Subunit of L-Type Ca2+ 
Channels (Cav1.2) and α1H T-type Ca2+ Channels 
(Cav3.2) Stably Expressed in Human Embryonic Kidney 
293 Cells
Jason L. Scragg, Richard D. Jones, T Hugh Jones, Kevin S. Channer, Chris Peers, The 
University of Leeds, Leeds, United Kingdom, The University of Sheffield, Sheffield, 
United Kingdom
Background: Testosterone therapy reduces myocardial ischaemia in men with coronary
artery disease (CAD) [1] and improves symptom scores and exercise capacity in men
with congestive heart failure (CHF) [2]. These effects may be attributed to a direct
vasodilatory efficacy in the coronary [3] and peripheral [4] vasculature. In vitro studies
suggest this vasodilatation is due to a calcium antagonistic action upon voltage-gated
Ca2+ channels [5], but this has yet to be investigated directly. Methods: We employed
patch clamp methodology to study the effect of testosterone (1nM-1µM) upon whole-cell
Ca2+ channel currents (using 20mM Ba2+ as the charge carrier) in HEK 293 cells stably
expressing either the main pore-forming α1C subunit of a human L-type Ca2+ channel
(Cav1.2), or the α1H T-type Ca2+ channel (Cav3.2) [6]. Results: Testosterone (1nM-1µM)
caused a rapid, irreversible concentration-dependent inhibition of L-type Ca2+ currents,
with an IC50 value of 61.0±0.6nM (n = 4-9 cells at each concentration tested). Current-
voltage relationships indicated that testosterone caused a similar inhibition at all activat-
ing potentials, suggesting that the inhibition was voltage-independent. Testosterone
(1nM-1µM) also inhibited currents mediated via T-type Ca2+ channels, but this effect was
partially reversible with a lower IC50 value of 231.9±0.7nM. Conclusions: Testosterone
acts as an inhibitor of both human L-type and T-type Ca2+ channels, the major voltage-
gated calcium channels expressed in vascular smooth muscle. Inhibition of L-type Ca2+
channels occurred at physiological concentrations. This calcium antagonistic action may
contribute to the clinical benefits associated with testosterone therapy in men with CAD
and CHF.
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1106-187 Both Beta-Blockers and Amiodarone Increase Speed of 
QT / Heart Rate Adaptation
Peter Smetana, Esther Pueyo, Katerina Hnatkova, Velislav Batchvarov, Marek Malik, 
St.George's Hospital Medical School, London, United Kingdom
Background: Recent studies gave evidence that the combination of amiodarone and beta
blocker (BB) treatment is beneficial. This therapeutic option may be relevant in many
areas including those of no clear indication for ICD. However, the mode of synergistic
action is still to be established. Since both substances were shown to modulate QT/RR
relationship we investigated a descriptor of QT rate adaptation speed in Holter recordings
of patients from the EMIAT database surviving the 2-year follow-up period.
Methods: In 754 (403 amiodarone, 351 placebo) 24-hour Holter recordings obtained 1
month after randomisation into EMIAT RR, and QT intervals were measured automati-
cally on a beat-to-beat basis using a commercial Holter system. The individual QT rate
adaptation profile was assessed on a continuous basis by quantifying the weighted
impact of RR interval history on each QT interval and expessing this by the so-called
lambda factor (LF). The smaller LF, the faster QT interval adaptation to heart rate.
Results were compared in patients on and off BB in the amiodarone and the placebo
group.
Results: Both amiodarone and BB increased the speed of QT adaptation to changes in
RR interval (LF: placebo vs placebo+BB, 50.4± 6.7 vs 47.4± 7.7, p=0.000006; amio-
darone vs amiodarone+BB: 47.9± 6.8 vs 43.1± 7.5, p=2× 10-11). Examples in the figure.
Conclusions: Both amiodarone and BB improve adaptation of QT interval to changes in
RR interval. This might be one of the reasons for the superior benefit of a combination of
the therapies. 
1106-188 Ghrelin Is Synthesized and Secreted by Human 
Cardiomyocytes Protecting These Cells From Apoptosis
José Ramón González-Juanatey, María J. Iglesias, Roberto Piñeiro, Oreste Gualillo, 
Montserrat Blanco, Carlos Diéguez, Francisca Lago, Hospital Clinico Universitario 
Santiago De Compostela, Santiago De Compostela, Spain, Universidad De Santiago De 
Compostela, Santiago De Compostela, Spain
Background: Ghrelin, the endogenous ligand of growth hormone secretagogue receptor
(GHS-R), acts on the pituitary and the hypothalamus to stimulate the release of growth
hormone (GH) and promote appetite and adiposity. It has also been reported to increase
myocardial contractility, induce vasodilation, and protect against myocardial-infarction-
induced heart failure. Though principally gastric in origin, it is also produced by other tis-
sues. This work investigated whether cardiomyocytes synthesize and secrete ghrelin,
and how its production in these cells responds to stress and exogenous apoptotic agents.
Methods and Results. RT-PCR showed that cells of the adult mouse cardiomyocyte line
HL-1 produce mRNAs for both ghrelin and GHS-R, and competitive binding studies using
125I-labelled ghrelin showed efficient constitutive expression of GHS-R at the surface of
HL-1 cells. Immunohistochemistry confirmed the presence of ghrelin in the cytoplasm of
HL-1 cells and of isolated human cardiomyocytes in primary culture. Radioimmunoassay
showed that ghrelin was secreted by HL-1 cardiomyocytes into the culture medium.
Ghrelin did not modify the viability of HL-1 cells subjected to 12
 
h starvation, but did pro-
tect against the apoptosis inducer cytosine arabinoside (AraC). Finally, production of
ghrelin mRNA in HL-1 cardiomyocytes was reduced by AraC but increased if exposure to
AraC was preceded by GH treatment.Conclusions. We demonstrate for the first time that
ghrelin is synthesized and secreted by isolated murine and human cardiomyocytes, prob-
ably with paracrine/autocrine effects protecting these cells from apoptosis. This new axis
may play a beneficial role in myocardial dysfunction and heart failure.
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825-1 Efficacy and Safety of Ximelagatran Compared With 
Well-Controlled Warfarin in Elderly Patients With 
Nonvalvular Atrial Fibrillation: Observations From the 
SPORTIF Trials
S. Bertil Olsson, for the Executive Steering Committee on Behalf ofthe SPORTIF 
Investigators, University Hospital, Lund, Sweden, Mount Sinai Medical Center, New York, 
NY
Background: Nonvalvular atrial fibrillation (AF) affects 5-10% of people over 75 years of
age, in whom the risk of thromboembolism is higher than in younger individuals. Although
adjusted-dose warfarin protects against ischemic stroke, many patients cannot sustain
treatment because of bleeding, drug interactions, and coagulation monitoring. The oral
direct thrombin inhibitor, ximelagatran (ExantaTM, AstraZeneca), is a potential alterna-
tive anticoagulant. Both treatments were compared in patients of at least 75 years.
Methods: The SPORTIF III (open-label, n = 3410) and V (double-blind, n = 3922) trials
included 2804 patients at least 75 years of age with AF and at least 1 stroke risk factor
randomized to adjusted-dose warfarin (target INR 2.0–3.0) or fixed-dose ximelagatran
(36 mg twice daily). The primary endpoint was stroke (ischemic or hemorrhagic) and sys-
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temic embolism based on blinded event assessment and intention-to-treat.
Results: During 4268 patient-years (mean 18 months), 96 primary events occurred. The
mean INR in the warfarin group (2.5±0.7) was within target range for 67% of follow-up.
The primary event rate was 2.27%/year with warfarin and 2.23%/year with ximelagatran,
relative risk reduction (RRR) 2% (95% CI –46%, 34%; p = NS). 66% of patients in the
warfarin arm and 69% in the ximelagatran arm completed the trial on assigned treatment.
On-treatment event rates were 2.09%/year and 1.82%/year in the warfarin and ximela-
gatran arms, respectively, RRR 13% (95% CI –38%, 45%; p = NS). Rates of disabling or
fatal stroke, mortality, and major bleeding were similar in both groups. Combined minor
and major hemorrhages were lower with ximelagatran than warfarin (40.0%/year vs
45.0%/year; RRR 11%, 95% CI 2%, 18%; p = 0.014). Within the first 6 months, serum
alanine aminotransferase levels rose >3 times the upper limit of normal in 29 patients on
warfarin (0.8%) vs 224 patients on ximelagatran (6.1%), but returned towards normal in
all cases.
Conclusion: In elderly, high-risk patients with AF, oral ximelagatran without coagulation
monitoring or dose adjustment was at least as effective for prevention of stroke and sys-
temic embolism, and associated with less bleeding than well-controlled warfarin.
4:15 p.m.
825-2 Efficacy and Safety of Ximelagatran Compared With 
Well-Controlled Warfarin in Women and Men With 
Nonvalvular Atrial Fibrillation in the SPORTIF Trials
Jonathan L. Halperin, for the Executive Steering Committee on Behalf ofthe SPORTIF 
Investigators, Mount Sinai Medical Center, New York, NY, City Hospital, Lund, Sweden
Background: Nonvalvular atrial fibrillation (AF) affects women less often than men, but
the risk of stroke is greater among women. Warfarin protects against stroke, but is asso-
ciated with bleeding, which occurs more often in women than in men. The oral direct
thrombin inhibitor, ximelagatran (ExantaTM, AstraZeneca), is a potential alternative anti-
coagulant to warfarin.
Methods: The SPORTIF III (open-label, n = 3410) and V (double-blind, n = 3922) noninfe-
riority trials included 2257 women with AF and at least 1 stroke risk factor randomized to
adjusted-dose warfarin (target INR 2.0–3.0) or fixed-dose ximelagatran (36 mg twice
daily). The mean age of female participants (73.4±8.0 years) was similar to that of the
5072 males (69.9±9.1 years). The primary endpoint was stroke (ischemic or hemor-
rhagic) and systemic embolism based on blinded assessment and intention-to-treat.
Results: During 11,233 patient-years (mean 19 months) exposure (3468 in women and
7765 in men) 72 primary events occurred in women and 112 in men. The mean INR with
warfarin (2.5±0.7) was within target range for 67% of follow-up for both genders. In
women, the primary event rate was 2.0%/year with warfarin and 2.2%/year with ximela-
gatran, relative risk reduction (RRR) –10% (95% CI –73%, 31%; p = NS); rates in men
were 1.5%/year and 1.4%/year (RRR 9.0%, 95% CI –32%, 37%; p = NS). On-treatment
event rates were 1.8%/year and 1.5%/year among women in the warfarin and ximelagat-
ran groups (RRR 16%, 95% CI –46%, 52%; p = NS) compared with 1.5%/year and 1.4%/
year among men (RRR 5%, 95% CI -40%, 36%; p = NS). Combined rates of minor and
major hemorrhages were greater among women (42.6%/year vs 36.9%/year on warfarin
and 33.8%/year vs 30.8%/year on ximelagatran; treatment difference in women:
p<0.0001). Within the first 6 months, serum alanine aminotransferase levels rose >3
times the upper limit of normal in 29 patients on warfarin (0.8%) vs 224 patients on ximel-
agatran (6.1%), but returned towards normal in all cases.
Conclusion: In both women and men with AF, oral ximelagatran without coagulation mon-
itoring or dose-adjustment was at least as effective as well-controlled warfarin for preven-
tion of thromboembolism, and was associated with less bleeding.
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825-3 Effect of Fosinopril on Cardiovascular Events in 
Relation to the Urinary Albumin Excretion
Folkert W. Asselbergs, Christiane A. Geluk, Hans L. Hillege, Adriaan A. Voors, Dirk J. van 
Veldhuisen, Paul E. de Jong, Wiek H. van Gilst, University of Groningen, Groningen, The 
Netherlands, University Hospital Groningen, Groningen, The Netherlands
Background ACE-inhibitors have shown to reduce albuminuria and cardiovascular
events in patients with hypertension. Our objective was to investigate whether the effect
of fosinopril on cardiovascular events differs between subjects with high or low urinary
albumin excretion (UAE).
Methods Prevention of REnal and Vascular ENdstage Disease Intervention Trial is a
double-blind, randomized, placebo-controlled trial with a 2x2 factorial design (n=864).
Subjects were randomized to fosinopril 20mg or matching placebo. Key entry criteria
were persistent microalbuminuria (15-300mg/24h) and no hypertension (<160/
100mmHg). UAE was measured in 2x24 hour urine collection. UAE was dichotomized
(low: first 4 quintiles, UAE < 50 mg/24h, high: upper quintiles, UAE > 50mg/24h).
Results Mean age was 51.3 ± 11.8 years, 65% was male, mean cholesterol was 223 mg/
dl, mean systolic blood pressure was 130 mmHg and mean diastolic blood pressure was
76 mmHg. During a mean follow-up period of 46.2 ± 7.0 months, 42 (4.9%) cardiovascu-
lar events occurred. The figure below shows the Cox regression analysis divided by UAE
and treatment. In the subjects with low UAE (group A), fosinopril reduced the events from
4.8 % to 3.0 % (relative risk reduction 37.5%). In the subjects with high UAE (group B),
fosinopril reduced the events from 13.0% to 5.3%, a relative risk reduction of 59.2%.
Conclusion Fosinopril reduces cardiovascular events to a greater extent in patients with
albumin excretion above 50 mg/24h.
4:45 p.m.
825-4 Effect of Fosinopril and Pravastatin on Carotid Intima-
Media-Thickness in Microalbuminuric Subjects Without 
Hypertension or Hypercholesterolemia
Folkert W. Asselbergs, Andries J. Smit, Gilles F.H. Diercks, Arie M. van Roon, Ad J. van 
Boven, Hans L. Hillege, Paul E. de Jong, Dirk J. van Veldhuisen, Wiek H. van Gilst, 
University of Groningen, Groningen, The Netherlands, University Hospital Groningen, 
Groningen, The Netherlands
Background ACE-inhibitors and HMG-CoA reductase inhibitors have shown to reduce
the progression of intima-media-thickness (IMT) in patient populations with hypertension
or hypercholesterolemia. PREVEND-IT investigated the effect of fosinopril and pravasta-
tin on IMT in non-hypertensive, non-hypercholesterolemic microalbuminuric subjects.
Methods Prevention of REnal and Vascular ENdstage Disease Intervention Trial is a
double-blind, randomized, placebo-controlled trial with a 2x2 factorial design (n=864).
Subjects were randomized to pravastatin 40 mg or matching placebo and to fosinopril
20mg or matching placebo. Key entry criteria were persistent microalbuminuria (15-
300mg/24h), no hypertension (<160/100mmHg) and no hypercholesterolemia (<308 mg/
dl). Microalbuminuria was measured in 2x24 hour urine collection. The IMT was mea-
sured at the posterior wall of the left common carotid artery using radio frequency signal
analysis obtained by M-mode ultra-sonography.
Results Mean age was 50.8 ± 11.4 years and 65% was male. The table below shows the
median IMT at baseline and after 4 years of follow-up divided by the different strategies.
These median IMT values are within the range of normal values found in our laboratory.
Conclusion Neither fosinopril and pravastatin showed an effect on the carotid IMT after
4 years of follow-up. The normal IMT values found in this population suggests that
microalbuminuria is an early risk indicator already present before detectable vascular
changes.
5:00 p.m.
825-5 Long-Term Bosentan Improves the Quality of Life of 
Patients With Pulmonary Arterial Hypertension
Adaani Frost, The BREATHE-1 Study Group, Baylor College of Medicine and the 
Methodist Hospital, Houston, TX
Background: Bosentan is an oral endothelin receptor antagonist that improves hemody-
namics and delays the time to clinical worsening in patients with pulmonary arterial
hypertension (PAH). In the BREATHE-1 study, the effect of long-term bosentan treatment
on the well being of PAH patients was investigated.
Methods: 213 patients with PAH (primary or associated with scleroderma) in WHO func-
tional class III or IV were enrolled in a double-blind, placebo-controlled study for 16
weeks (2:1 bosentan:placebo). Of these patients, 48 (35 bosentan; 13 placebo) contin-
ued double-blind study medication for up to 28 weeks (median exposure 26.9 weeks for
bosentan, 26.3 weeks for placebo). Patients received bosentan (62.5 mg bid for 4 weeks
then 125 or 250 mg bid) or placebo. Efficacy endpoints included the 6-minute walk dis-
tance, Borg dyspnea index and WHO functional class.
Results: Bosentan significantly improved the 6-minute-walk distance at Week 16 (+36 ±
6 m, mean ± sem) compared to placebo (-8 ± 12 m), (p < 0.001, n = 213), and the
improvement was maintained for up to 28 weeks (bosentan: +43 ± 14 m; placebo +6 ± 21
m, n = 48). In parallel, the Borg dyspnea index was decreased with bosentan and
increased with placebo resulting in a mean treatment effect of -0.6 (CI: [-1.2 -0.1]) at
week 16 (p =0.05, n =213) which was maintained (-0.8; CI: [-2.0 +0.3], n = 48) for up to
28 weeks. At Week 16, more patients on bosentan than on placebo showed an improve-
ment in WHO functional class (42.4% versus 30.4%, p = 0.04, n = 213). In the 48 patients
studied up to week 28, there was no significant difference in percentage of patients with
improvement over baseline in WHO class between the bosentan and placebo groups
Effect of treatment on IMT (mm), expressed as median (interquartile range)
placebo pravastatin fosinopril combination
IMT baseline 0.75 (0.64-0.86) 0.73 (0.64-0.88) 0.73 (0.66-0.84) 0.74(0.67-0.88)
IMT after 4 
year
0.81 (0.68-0.93) 0.80 (0.68-0.93) 0.78 (0.68-0.89) 0.77 (0.69-0.92)
Delta IMT 0.05 (-0.05-
0.16)
0.05 (-0.04-
0.13)
0.03 (-0.05-
0.11)
0.05 (-0.04-
0.13)
